FY2025 EPS Estimates for Henry Schein Increased by Analyst

Henry Schein, Inc. (NASDAQ:HSIC) – Equities research analysts at Barrington Research boosted their FY2025 EPS estimates for Henry Schein in a report released on Wednesday, November 5th. Barrington Research analyst M. Petusky now anticipates that the company will earn $4.90 per share for the year, up from their previous forecast of $4.81. Barrington Research has a “Outperform” rating and a $79.00 price objective on the stock. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Barrington Research also issued estimates for Henry Schein’s Q4 2025 earnings at $1.27 EPS, Q1 2026 earnings at $1.19 EPS, Q2 2026 earnings at $1.21 EPS, Q3 2026 earnings at $1.39 EPS, Q4 2026 earnings at $1.41 EPS, FY2026 earnings at $5.20 EPS and FY2027 earnings at $5.65 EPS.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.27 by $0.11. The company had revenue of $3.34 billion for the quarter, compared to analyst estimates of $3.28 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS.

Other equities research analysts also recently issued reports about the company. Leerink Partners set a $75.00 price objective on Henry Schein in a report on Monday, July 14th. Robert W. Baird reissued a “neutral” rating and issued a $72.00 price objective (down from $82.00) on shares of Henry Schein in a report on Monday, July 14th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Henry Schein in a report on Friday, October 31st. UBS Group decreased their price target on Henry Schein from $75.00 to $70.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Finally, Morgan Stanley increased their price target on Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a report on Wednesday. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $76.08.

Henry Schein Price Performance

HSIC stock opened at $72.01 on Thursday. The company has a market capitalization of $8.73 billion, a P/E ratio of 23.23, a PEG ratio of 2.06 and a beta of 0.84. Henry Schein has a twelve month low of $60.56 and a twelve month high of $82.49. The business has a 50 day simple moving average of $66.23 and a 200-day simple moving average of $68.64. The company has a current ratio of 1.41, a quick ratio of 0.78 and a debt-to-equity ratio of 0.51.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HSIC. Ameriprise Financial Inc. raised its stake in shares of Henry Schein by 3,275.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after buying an additional 2,199,695 shares during the last quarter. Norges Bank acquired a new position in shares of Henry Schein during the 2nd quarter worth $89,476,000. M.D. Sass LLC acquired a new position in shares of Henry Schein during the 2nd quarter worth $79,201,000. Schroder Investment Management Group raised its stake in shares of Henry Schein by 149.3% during the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after buying an additional 936,471 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Henry Schein by 204.2% during the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after buying an additional 668,182 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.